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Introduction 
The inhaled corticosteroid fluticasone propionate (FP) 
was introduced into the Thorpewood General Practice, 
Norwich, U.K. in 1993 -initially in treating relatively 
severe asthmatics. Observed beneficial effects led to 
expanded use - particularly for poorly controlled asthma 
not responsive to increased inhaled anti-inflammatories. 
However, an early review suggested little advantage over 
existing agents (l), and FP was marketed at a price pre- 
mium. The aims of this study were to investigate whether 
continued and expanding use of FP was justified in terms 
of improved clinical outcomes, and if such improvements 
were associated with reduced NHS costs (offsetting more 
expensive prescriptions). A controlled, retrospective, non- 
randomized primary care audit compared clinical outcomes 
and asthma management costs 1 year prior to and 1 year 
into FP therapy. 
Patients and Methods 
Patients studied were diagnosed asthmatics registered at the 
practice and monitored regularly. The treatment group 
comprised those patients (n=21) first prescribed FP during 
1993. Their final year of treatment prior to FP therapy 
(Year 1) was compared with their first full year on FP 
(Year 2) (4192-l 1194). Changes in practice staff or clinical 
procedures can affect clinical outcomes and/or costs, and a 
second group of patients was included as a control for such 
non-drug effects. These patients (n=24) were first pre- 
scribed FP in 1994 subsequent to the period of study, and 
were followed over the 2-year period immediately preceding 
(l/92-7/94). The rationale for studying patients subse- 
quently given FP was that their asthma was likely to be 
similar to the treatment group. Demographic and baseline 
comparisons were made and reasons for prescribing FP 
(and at what dosage) noted. The following asthma manage- 
ment data were collected and Year 1: Year 2 comparisons 
were made: 
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l Peak expiratory flow (PEF) measurements 
l Number/type prescriptions - short-acting &agonist 
inhalers, courses of oral prednisolone 
l Number/type general practice consultations - surgery 
(GP/nurse) and home visits (day/night) 
l Hospital attendance - outpatient/admissions 
Where numbers justified formal statistical analysis 
and Year 1:Year 2 changes were normally distributed, 
paired t-tests were employed. Otherwise, the Wilcoxon 
signed-rank test was used (exact methods as appropriate). 
All tests were two-sided and used a significance level 
of 5%. 
Healthcare and prescriptions were costed, and total man- 
agement costs per patient were calculated. Sources for unit 
costs varied according to category but were generally based 
on practice/local authority estimates for 1994. 
Results 
BASELINE COMPARISONS 
Demography (gender, smoking, asthma duration) was 
broadly similar. Median dosage of inhaled corticosteroid 
(beclomethasone dipropionate or budesonide) was the same 
for both groups (8OOgg day - ‘). Median FP dosage was 
500 pug day - ‘. The two main reasons for prescribing FP 
were persistent symptoms (around 50% patients in both 
groups) and frequent exacerbations ( N 20%). 
CLINICAL OUTCOMES -YEAR 1: YEAR 2 
COMPARISONS 
l Percentage predicted mean PEF increased by a mean 
difference of 9.1% (P=O.OOl) in the FP group with little 
change in the controls. 
l The median number of short-acting bronchodilator pre- 
scriptions was halved from 8 to 4 (P=<O.OOl) with no 
corresponding fall in the control group. There was a 
reduction from 39 to 19% in the proportion of FP 
patients prescribed 10 or more items. 
l Among FP patients, the median number of prescriptions 
of oral prednisolone fell from 1 to zero (P=O.O37), with 
the proportion having zero courses increasing from 29 to 
71% [Fig. l(a)]. 
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FIG. 1. (a) Number of oral prednisolone courses prescribed during each year. (b) Frequency of GP clinic visits during 
each year. (c) Frequency of nurse clinic visits during each year. (d) Change in mean patient asthma medication and other 
asthma management costs during each year. 
l Surgery visits decreased significantly during FP treat- drop in the proportion of patients making five or more 
ment. The median frequency of GP consultations fell GP visits; and (ii) a 72 to 34% drop in the proportion 
from 4 to 2 per year (P=O.OOl) [Fig. l(b)], and for asthma seeing the asthma nurse three or more times. 
nurse attendances from 4 to 1 (P=O.O06) [Fig. l(c)]. By l The small number of GP home visits and hospital attend- 
contrast, control group GP consultations remained antes precluded statistical comparison, although there 
steady (median number 2) and nurse attendance were recorded reductions in the FP group for Year 2. 
increased (mean difference +0.9, P=O.O3). Two notable l One patient (FP group) was admitted to hospital in 
reductions in the treatment group were (i) a 48 to 10% Year 1. 
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COST COMPARISONS - YEAR 1: YEAR 2 
The average percentage change in total costs per patient for 
the FP group was +0,5%(&2)-a 39%(f91) increase in 
medication costs almost completely offset by a 64%(&90) 
reduction in other management costs [Fig. l(d)]. The 
control group was cheaper to manage throughout, but 
average total costs rose by 28%(0(&61) [drug +27%(&46), 
consultations +31%(&15)]. 
Discussion 
Changes in all primary outcome criteria investigated- 
percentage predicted peak expiratory flow (PEF) as a 
measure of lung function, short-acting bronchodilator pre- 
scriptions as a marker for symptoms; oral prednisolone 
prescriptions for exacerbations and surgery attendance as 
an overall measure of asthma control- indicated that 
switching inhaled anti-inflammatory therapy to FP was 
associated with significant patient benefits. 
l The increased percentage predicted peak flow observed 
during FP treatment is likely to be clinically significant, as 
studies with smaller changes in lung function have been 
associated with improved asthma symptom scores (2). 
l The fall in the number of FP patients collecting 10 or 
more short-acting bronchodilator prescriptions (from 
8 to 4) is of particular interest. ‘Weaning off reliever 
medication in a high-use group is often regarded as either 
medically or behaviourally difficult, with some studies 
finding increased bronchodilator prescribing associated 
with improving care or higher inhaled steroid prescribing 
(3,4). 
l The decrease in GP and nurse consultations is hard to 
explain as a non-drug effect, since no reduction occurred 
in the control group. Moreover, the decrease is set against 
a trend of increased consulting generally and for asthma 
in particular (5). 
Average asthma medication costs increased substantially 
more for FP patients than for the controls [39%(&91) vs 
27%(&46)]. However, when other healthcare costs were 
taken into account, the increase in costs for FP treatment 
was very small - on average, 0.5%(&2) per patient. More- 
over, this minimal increase was associated with a marked 
improved in ‘healthiness’ as measured by all the primary 
outcome markers, whereas increased costs for the control 
group brought no such improvement. 
Apparent improvements seen in the FP treatment group 
might be due to increased patient adherence to the 
prescribed treatment regimes of a new drug, with attendant 
potential benefits. There was, however, no increase in 
repeat prescriptions to suggest significantly improved com- 
pliance, and any such effect is likely to be transient. Any 
benefit could also be due to an increase in effective inhaled 
corticosteroid dose, rather than the change to a new drug. 
However, the median dose of inhaled corticosteroids fell 
from 8OOpg (BDP and budesonide) to 5OOpg (FP). 
Changes in delivery device may also be cited, but there was 
little change in devices from Year 1 to Year 2. 
The design limitations of this study - chiefly that it was 
retrospective and non-randomized - restrict the degree of 
data analysis that is justifiable and the extent to which 
observed effects may be interpreted as irrefutable fact. 
Selection of patients for the control group was not ideal but 
was, again, dictated by the retrospective nature of the 
study. However, and despite these limitations, the data 
collected strongly indicate that for asthmatics with persist- 
ent symptoms and frequent exacerbations, switching to 
FP therapy can bring an improvement in clinical outcomes 
and be cost-effective in terms of total NHS costs. In 
order to verify these initial findings, a prospective, 
clinically-controlled, double-blind study is currently being 
undertaken. 
References 
1. Fluticasone propionate for asthma prophylaxis. Drug 
Therapeut Bull 1994; 32: 25-27. 
2. Barnes NC, Marone G, Di Maria GU, Visser S, Utama 
I, Payne SL. A comparison of fluticasone propionate, 
1 mg daily, with beclomethasone dipropionate, 2 mg 
daily, in the treatment of severe asthma. Eur Respir J 
1993; 6: 8777884. 
3. Vile C. Asthma audit. Pratt Nurse 1992; 226-229. 
4. Jones K. Impact of an interest in asthma on prescribing 
costs in general practice. Qua1 Health Care 1992 1: 
110-113. 
5. Royal College of General Practitioners, Office of Popu- 
lation Censuses and Surveys, and Department of Health. 
Morbidity statistics from general practice. Fourth 
National Study 1991-1992. London: HMSO 1995. 
